Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acorda Therapeutics (ACOR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 365,788
  • Shares Outstanding, K 48,130
  • Annual Sales, $ 471,430 K
  • Annual Income, $ 33,680 K
  • 60-Month Beta 1.37
  • Price/Sales 0.78
  • Price/Cash Flow 3.23
  • Price/Book 0.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.22
  • Number of Estimates 4
  • High Estimate -1.09
  • Low Estimate -1.40
  • Prior Year 1.29
  • Growth Rate Est. (year over year) -194.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.96 +8.19%
on 06/12/19
11.91 -36.78%
on 05/16/19
-3.60 (-32.35%)
since 05/14/19
3-Month
6.96 +8.19%
on 06/12/19
14.96 -49.67%
on 03/18/19
-7.07 (-48.42%)
since 03/14/19
52-Week
6.96 +8.19%
on 06/12/19
31.55 -76.13%
on 06/15/18
-23.97 (-76.10%)
since 06/14/18

Most Recent Stories

More News
Dr. Reddy's Inks Deal to Sell Neurology Branded Products

Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.

ANIK : 39.77 (-1.51%)
RDY : 37.07 (+0.43%)
ACOR : 7.53 (-0.92%)
AGTC : 3.88 (+1.57%)
Acorda Therapeut Has Returned 43.6% Since SmarTrend Recommendation (ACOR)

SmarTrend identified a Downtrend for Acorda Therapeut (NASDAQ:ACOR) on February 19th, 2019 at $13.92. In approximately 4 months, Acorda Therapeut has returned 43.61% as of today's recent price of $7.85....

ACOR : 7.53 (-0.92%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Myriad Genetics (MYGN , ACOR , KPTI , INSM , CYTK )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

MYGN : 24.01 (-7.62%)
KPTI : 5.71 (-0.70%)
ACOR : 7.53 (-0.92%)
Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi

Catalyst Pharma (CPRX) files lawsuit against FDA's approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.

ANIK : 39.77 (-1.51%)
ACOR : 7.53 (-0.92%)
AGTC : 3.88 (+1.57%)
CPRX : 3.80 (-1.30%)
NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag

The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer

LLY : 111.74 (-0.07%)
RGEN : 74.22 (-1.01%)
ACOR : 7.53 (-0.92%)
NCNA : 11.94 (+2.49%)
Acorda Therapeutics Enters Oversold Territory

Acorda Therapeutics, Inc. (ACOR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

ACOR : 7.53 (-0.92%)
Denali's Hunter Syndrome Candidate Gets Orphan Drug Status

The FDA assigns an orphan drug designation and a rare pediatric disease designation to Denali's (DNLI) pipeline candidate, DNL310, for treating patients with Hunter Syndrome. Shares inch up.

SGMO : 9.31 (-3.02%)
DNLI : 18.71 (-1.73%)
RGEN : 74.22 (-1.01%)
ACOR : 7.53 (-0.92%)
Athenex Rallies on Positive Early Data on Psoriasis Candidate

Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for treating patients with psoriasis.

ATNX : 17.80 (+2.83%)
MRUS : 13.40 (+0.68%)
RGEN : 74.22 (-1.01%)
ACOR : 7.53 (-0.92%)
Acorda Therapeut Down 42.9% Since SmarTrend Downtrend Call (ACOR)

SmarTrend identified a Downtrend for Acorda Therapeut (NASDAQ:ACOR) on February 19th, 2019 at $13.92. In approximately 4 months, Acorda Therapeut has returned 42.89% as of today's recent price of $7.95....

ACOR : 7.53 (-0.92%)
Watch for Acorda Therapeut to Potentially Rebound After Falling 6.71% Yesterday

Acorda Therapeut (NASDAQ:ACOR) traded in a range yesterday that spanned from a low of $8.00 to a high of $8.07. Yesterday, the shares fell 6.7%, which took the trading range below the 3-day low of $8.39...

ACOR : 7.53 (-0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ACOR with:

Business Summary

Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis....

See More

Key Turning Points

2nd Resistance Point 8.04
1st Resistance Point 7.79
Last Price 7.53
1st Support Level 7.38
2nd Support Level 7.22

See More

52-Week High 31.55
Fibonacci 61.8% 22.16
Fibonacci 50% 19.25
Fibonacci 38.2% 16.35
Last Price 7.53
52-Week Low 6.96

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar